Hodgkin’s Lymphoma Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharma, 4SC, TG Therapeutics

Hodgkin's Lymphoma Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) -  DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharma, 4SC, TG Therapeutics
Delveinsight Business Research LLP
As per DelveInsight, the Hodgkin’s Lymphoma Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Hodgkin’s Lymphoma and the launch of new therapies in the market. There are a few emerging key players, which are expected to enter the Hodgkin Lymphoma market in the coming years, which includes ADC Therapeutics (ADCT-301), BeiGene (Tislelizumab), Tessa Therapeutics (Autologous CD30), and others.

DelveInsight’s “Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hodgkin’s Lymphoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Hodgkin’s Lymphoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hodgkin’s Lymphoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hodgkin’s Lymphoma: An Overview

According to the National Organization for Rare Diseases, Hodgkin’s disease comprises a group of cancers, which are known as lymphoma. Lymphoma is a general term used to describe cancers that affect the lymphatic system, especially the lymph nodes. Tumors often form in the lymph nodes and/or the area around the nodes.

With the help of some preliminary research, it has been seen that Hodgkin lymphoma can result due to multifactorial causes. These are due to an infectious agent, such as a virus (e.g., Epstein Barr Virus). Recent studies indicate that there may be a genetic susceptibility to Hodgkin’s disease in the young adult form of the disorder as well, environmental factors or immune system deficiencies may also play a role in the development of Hodgkin’s disease. Usually, the first sign of Hodgkin’s disease is a swollen lymph node. Two-thirds of the time, a lymph node in the neck is affected. Otherwise, lymph nodes in the armpits, chest, groin, or abdomen are affected. The disease may also spread to other lymph nodes, the area around the nodes, the spleen, liver, lungs, and bone marrow.

A variety of X-ray tests may be used to determine how far the disease has spread including CT scans, magnetic resonance imaging (MRIs), and a special x-ray technique that focuses on the lymphatic system (lymphangiogram). Treatment of Hodgkin’s disease depends on the stage of the disease. Radiotherapy and/or chemotherapy are the two main treatment options.

Hodgkin’s Lymphoma Market Key Facts

  • According to the National Organization of Rare Diseases (NORD), the majority of individuals with the adult form of Hodgkin’s disease are between 15 and 40 years of age at the time of diagnosis. A smaller number of individuals are affected after the age of 50. Hodgkin’s disease may also affect children. HL disease accounts for less than 1% of all cases of cancer in the United States.

  • As per a systemic review by Hjalgrim et al., (2013) titled, “Epidemiology of Hodgkin Lymphoma”, Hodgkin lymphoma is a lymphatic malignancy with an estimated annual incidence of 80,000 cases worldwide.

  • As per the NHS (UK), Hodgkin lymphoma can develop at any age, but it mostly affects young adults in their early 20s and older adults over the age of 70. Slightly more men than women are affected. Around 2,100 people are diagnosed with Hodgkin lymphoma in the UK each year.

  • The American Cancer Society’s estimates for Hodgkin lymphoma in the United States for 2021 are about 8,830 new cases (4,830 in males and 4,000 in females). Moreover, it was reported that both children and adults can develop Hodgkin lymphoma, but it’s most common in early adulthood (especially in a person’s 20s).

Hodgkin’s Lymphoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hodgkin’s Lymphoma pipeline therapies. It also thoroughly assesses the Hodgkin’s Lymphoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Hodgkin’s Lymphoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hodgkin’s Lymphoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Hodgkin’s Lymphoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hodgkin’s Lymphoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Hodgkin’s Lymphoma Epidemiology, Segmented as –

  • Total Incident Cases of Hodgkin’s Lymphoma

  • Age-specific incident Cases of Hodgkin’s Lymphoma

  • Gender-specific incident Cases of Hodgkin’s Lymphoma

  • Incident Population of Relapsed/ Refractory form of Hodgkin Lymphoma

  • Treatable cases of Relapsed/ Refractory Hodgkin Lymphoma (R/R HL)]

Hodgkin’s Lymphoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hodgkin’s Lymphoma market or expected to be launched during the study period. The analysis covers the Hodgkin’s Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hodgkin’s Lymphoma drugs based on their sale and market share.

The report also covers the Hodgkin’s Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hodgkin’s Lymphoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Hodgkin’s Lymphoma Market Will Evolve and Grow by 2032 @ 


Hodgkin’s Lymphoma Therapeutics Analysis

Chemotherapy and radiation therapy are the main treatments for Hodgkin Lymphoma. Depending on the case, one or both of these treatments might be used. Certain patients might be treated with immunotherapy or with a stem cell transplant, especially if other treatments have not worked. Except for biopsy and staging, surgery is rarely used to treat the condition.

Several major pharma and biotech companies are developing therapies for Hodgkin’s Lymphoma. Currently, Affimed Therapeutics is leading the therapeutics market with its Hodgkin’s Lymphoma drug candidates in the mid to advanced stage of clinical development.

Hodgkin’s Lymphoma Companies Actively Working in the Therapeutics Market Include

  • Affimed Therapeutics

  • ACD Therapeutics

  • Cstone Pharmaceuticals

  • 4SC

  • TG Therapeutics

And Many Other

Emerging and Marketed Hodgkin’s Lymphoma Therapies Covered in the Report Include:

  • AFM 13: Affimed Therapeutics

Affimed Therapeutics’ new drug candidate, AFM 13, is a type of immunotherapy, currently in the development stage for the treatment of Hodgkin’s disease. Phase I data demonstrated good efficacy and tolerability. The drug has been designated with orphan drug status. The drug does not kill cancer cells directly but encourages the body’s own immune system to seek out and destroy the cells. It works by activating a type of immune cell, called a natural killer (NK) cell, and directing them to destroy the cancerous cells.

  • Camidanlumab tesirine: ACD Therapeutics

ACD Therapeutics’ “breakthrough” drug carnidanlumab tesirine is currently being evaluated for the treatment of Hodgkin’s lymphoma and has demonstrated safety and efficacy in phase I trials. It is an antibody-drug conjugate against CD25 expressed on the surface of cancerous cells.

Similarly, other major players, which are expected to enter the Hodgkin Lymphoma market in the coming years include BeiGene (Tislelizumab), Tessa Therapeutics (Autologous CD30), and others. The launch of these therapies is expected in the near future. 

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hodgkin’s Lymphoma Competitive Intelligence Analysis

4. Hodgkin’s Lymphoma Market Overview at a Glance

5. Hodgkin’s Lymphoma Disease Background and Overview

6. Hodgkin’s Lymphoma Patient Journey

7. Hodgkin’s Lymphoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Hodgkin’s Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Hodgkin’s Lymphoma Unmet Needs

10. Key Endpoints of Hodgkin’s Lymphoma Treatment

11. Hodgkin’s Lymphoma Marketed Therapies

12. Hodgkin’s Lymphoma Emerging Drugs and Latest Therapeutic Advances

13. Hodgkin’s Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Hodgkin’s Lymphoma Market Outlook (In US, EU5, and Japan)

16. Hodgkin’s Lymphoma Companies Active in the Market

17. Hodgkin’s Lymphoma Access and Reimbursement Overview

18. KOL Views on the Hodgkin’s Lymphoma Market

19. Hodgkin’s Lymphoma Market Drivers

20. Hodgkin’s Lymphoma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hernia Repair Devices Market

The global Hernia Repair Devices Market was valued at USD 4.00 billion in 2021 and growing at a CAGR of 5.08% during the forecast period from 2023 to 2028; it is expected to reach USD 5.38 billion by 2028. Some of the leading companies such as Medtronic, Johnson & Johnson, Inc., B. Braun Melsungen AG, Cook, Gem Srl, PRIMEQUAL SA, Becton, Dickinson and Company, Deep Blue Medical Inc., Meril Life Sciences Pvt. Ltd., Changzhou Medical Equipment General Factory Co., Ltd., Sinolinks Medical Innovation, Inc., W.L. Gore & Associates, Herniamesh® S.r.l., KATSAN Katgüt Sanayi ve Tic. A.Ş., Dipromed Srl, BioCer Entwicklungs-GmbH, SAMYANG HOLDING CORPORATION, Betatech Medical, Cousin Surgery, Aspide Medical S.A.S., among others, are actively working in the Hernia Repair Devices Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology